Info

You have entered the address of a Kleresca® site outside your country. Please be aware that information on the site may not apply to your country.

Stimulate the skin's own repair mechanisms

Nothing added, just skin at its best

The Kleresca® way - effect without compromise

At Kleresca®, we aspire to transform the way skin is treated. Our innovative biophotonic platform creates a mode of action unique in the field of dermatology. Working with scientific rigour, and together with leading professional clinics, we strive to continue challenging the conventions of the industry.
The Kleresca® biophotonic platform offers non-invasive treatments2,10 for both therapeutic and aesthetic conditions using fluorescent light to stimulate the skin’s own biological processes and repair mechanisms.
Our treatments reduce inflammation11, increase the build-up of collagen and normalise cellular activity4-9 with high safely and efficacy2,7. In scientific terms, the process is known as photobiomodulation.

 

Fluorescent light energy (FLE)

Kleresca® is the only technology on the market using FLE to activate the skin from within5-15. It is a completely new mode of action that has been on the market since 2014. The treatment can be applied all year-round, including summer, helping patients achieve balanced and glowing skin5-15.

Learn more about the biophotonic technology

*For references click here. 

Distributed by:

Klox Technologies Europe Limited
51 Bracken Road
Sandyford Industrial Estate
Dublin 18
Ireland

FB Dermatology
© 2020.

Corp Reg.no.: IE 595931
All trademarks, including Kleresca, mentioned belong to FB Dermatology Ltd.

Contact us

We would like to hear from you! Click here to contact us

Kleresca® uses cookies to give you the best experience online and to provide anonymised, aggregated site usage data. By clicking "Yes, I agree", you consent to this use of cookies. You can find out what cookies we use, what they do and how you can disable them in our Cookie Policy. You can find more related information in our Privacy Policy.